RE:RE:RE:OA & Back pain worth Doccole wrote: Worth noting-
dano spoke about how big pharm likes (platforms)gene editing or cancer platforms. I feel ate is building out our specific platform for a offer.
I just wonder how much it will be? if it happens! With Huat in the picture, guessing big....I bought more today. I was going to wait until the AH news. Heck with it! Load me up!
Yes - and this platform (gaseous mediators) is very young and not well known.
There are a lot of moving parts to develop and to push forward if we want top dollar.
Even if Big Pharma is interested, we have a lot to prove if we want to be paid properly - IMO.
The patents have been reviewed by 3rd parties back in 2018-19 so that should be sufficient for Big Pharma to evaluate. At that time, they also worked out the general drug development strategy that we are following now - to show the world what "gaseous mediators" are all about.
Then you have the first in a family of drugs to show success in P2A/B trials - which puts us on the map. The further you move 352 and 340 to human trials, the more valuable we become. The larger the number of new potential products, the more valuable we become.
If I were to guess what it's going to take before we strike an acceptable deal ... probably looks something like this ...
1. OTENA well into P3 where the dose has been set the the program recalibrated based on the finalized dosing plan.
2. ATB-352 in human testing (maybe even P1 completed successfully and fast-track expected).
3. Aspirin with a new molecule preparing for human testing OR more colour regarding this COVID trial (anti-infammatory, anti-viral, reduced oxidative cell damage and improved immune response - guessing it's all about the immune system for pre-existing conditions and the elderly) ... either one will advance Big Pharma's desire to dish out the big bucks.
4. Additional new drug candidates to add to IBD and to show that we have a process that turns new drug candidates onto our roster with precision. Make it Alzheimer's or Parkinson's related and score bonus points.
Then again ... maybe we have enough data to show and to guide Big Pharma into understanding what we have here. I'm just not convinced we're there yet. We have work to do.